Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
复制标题
DOI：
10.1186/1475-2875-9-48
复制
发表时间：
2010-02-11
期刊：
影响因子：
3
通讯作者：
Genton, Blaise
中科院分区：
文献类型：
--
作者：
Kabanywanyi, Abdunoor M.;Lengeler, Christian;Genton, Blaise
背景：对照临床试验表明，采用六剂蒿甲醚-本芴醇 (AL) 治疗无并发症的恶性疟原虫疟疾的治愈率 >95%，且耐受性良好。 材料和方法：进行了一项前瞻性研究，以记录 AL 给药的依从性和可接受性。这是在 ALIVE 研究的背景下进行的，这是一项在坦桑尼亚农村疟疾流行地区进行的前瞻性、基于社区的观察性研究。在显微镜下确认恶性疟原虫感染后，第一剂 AL 剂量是在监督下服用的，随后的五剂剂量是在无人监督的情况下在家中服用的。患者被随机分配在接近预定时间的情况下接受家庭评估，其中一种无人监督的剂量，但不知道他们被分配的后续访问。由训练有素的工作人员进行结构化调查问卷，并通过检查泡罩包装确认 AL 消耗量。 结果：总共招募了 552 名患者，其中 352 名（63.8%）是
Background: Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability.Materials and methods: A prospective study was carried out to document the adherence to and acceptability of AL administration. This was undertaken in the context of the ALIVE study, a prospective, community-based, observational study in a rural, malaria-endemic area of Tanzania. Following microscopic confirmation of P. falciparum infection, the first AL dose was taken under supervision, with the subsequent five doses taken unsupervised at home. Patients were randomized to receive a home-based assessment close to the scheduled time for one of the unsupervised doses, but were blinded to which follow-up visit they had been allocated. A structured questionnaire was administered by trained staff and AL consumption was confirmed by inspection of blister packs.Results: A total of 552 patients were recruited of whom 352 (63.8%) were